Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 158

Showing 51-75 of 158 citing articles:

Additional Oncogenic Alterations inRAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Athanasios Bikas, Sara Ahmadi, Θεοδώρα Παππά, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2678-2685
Open Access | Times Cited: 9
Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance
Enrique Rozengurt, Guido Eibl
Cancers (2021) Vol. 13, Iss. 20, pp. 5126-5126
Open Access | Times Cited: 23
Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling
Yuandeng Luo, Xiaoyu Liu, Lei Fang, et al.
Theranostics (2022) Vol. 12, Iss. 18, pp. 7903-7919
Open Access | Times Cited: 14
Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors
Kotaro Sakamoto, Yun Qi, Eijiro Miyako
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer
Mai Thi Le, Nguyen Thu Huyen, Xuan‐Hung Nguyen, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e22080-e22080
Open Access | Times Cited: 8
Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
Adelina Plangger, Barbara H. Rath, Sandra Stickler, et al.
Discover Oncology (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 13
Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
Daniel J Sisler, Trista K. Hinz, Anh‐Tuan Le, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Regulation of Ras Signaling by S-Nitrosylation
Sónia Simão, Rafaela Ribeiro Agostinho, Antonio Martı́nez-Ruiz, et al.
Antioxidants (2023) Vol. 12, Iss. 8, pp. 1562-1562
Open Access | Times Cited: 7
Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review
Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 3
Open Access | Times Cited: 2
A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancer
Ishwaree Datta, Tajah Vassel, Benjamin Linkous, et al.
G3 Genes Genomes Genetics (2023) Vol. 13, Iss. 5
Open Access | Times Cited: 6
Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders
Sofie Haglund, Jan Söderman, Sven Almér
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5820-5820
Open Access | Times Cited: 6
ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways
Keyu Li, Lingli Quan, Fang Huang, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110580-110580
Closed Access | Times Cited: 6
CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells
Xiaochen Liu, Fei Tian, Jianfeng Cui, et al.
Oncogene (2023) Vol. 42, Iss. 42, pp. 3113-3126
Closed Access | Times Cited: 6
microRNA-324-3p suppresses the aggressive ovarian cancer by targeting WNK2/RAS pathway
Fengjie Li, Zhen Liang, Yongqin Jia, et al.
Bioengineered (2022) Vol. 13, Iss. 5, pp. 12030-12044
Open Access | Times Cited: 10
Licoricidin combats gastric cancer by targeting the ICMT/Ras pathway in vitro and in vivo
Hanwei Ma, Fahong Wu, Yinliang Bai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma
Lili Mao, Jun Guo, Lingjun Zhu, et al.
European Journal of Cancer (2022) Vol. 175, pp. 125-135
Closed Access | Times Cited: 9
Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity
Tâmara Dauare de Almeida, Fernanda Cristina Gontijo Evangelista, Adriano de Paula Sabino
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 162-179
Open Access | Times Cited: 5
Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells
J.H. Lee, Sang Hyub Lee, Sang Kook Lee, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2642-2642
Open Access | Times Cited: 5
The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
Fernanda Andrade, Júlia German-Cortés, Sara Montero‐Herradón, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1686-1686
Open Access | Times Cited: 5
Signalling in pancreatic cancer: from pathways to therapy
Kexun Zhou, Yingping Liu, Shiman Yuan, et al.
Journal of drug targeting (2023) Vol. 31, Iss. 10, pp. 1013-1026
Closed Access | Times Cited: 5
In Peripheral Blood Mononuclear Cells Helicobacter pylori Induces the Secretion of Soluble and Exosomal Cytokines Related to Carcinogenesis
Josefina Atrisco-Morales, Mónica Ramı́rez, Carlos Alberto Castañón-Sánchez, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8801-8801
Open Access | Times Cited: 8
Molecular Effects of Iodine-Biofortified Lettuce in Human Gastrointestinal Cancer Cells
Olga Sularz, Aneta Koronowicz, Cayla Boycott, et al.
Nutrients (2022) Vol. 14, Iss. 20, pp. 4287-4287
Open Access | Times Cited: 8
Using molecular characteristics to distinguish multiple primary lung cancers and intrapulmonary metastases
Zhenhua Li, Huilai Lv, Fan Zhang, et al.
PeerJ (2024) Vol. 12, pp. e16808-e16808
Open Access | Times Cited: 1
Bone absorption and deformity in mandible as initial symptom and manifestation of neurofibromatosis type 1: A case report and literature review
Lini Deng, Yi Wang, Xianwang Xiang, et al.
Oral Oncology Reports (2024), pp. 100132-100132
Open Access | Times Cited: 1
Transcription factor EHF interacting with coactivator AJUBA aggravates malignancy and acts as a therapeutic target for gastroesophageal adenocarcinoma
Li Peng, Yan‐Yi Jiang, Hengxing Chen, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 2119-2136
Open Access | Times Cited: 1

Scroll to top